Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

rehdvm2004 7 posts  |  Last Activity: Jun 21, 2016 6:26 PM Member since: Oct 21, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Why would a patient want to take a "pill" (twice per day) for a lung infection when your could inhale a mist of the same antibiotic for 10 minutes and achieve the same result (without side effects from taking a pill)? The antibiotic does not have to be absorbed from the GI tract, equilibrate in the blood, circulate to the lungs (the infected organ) and kill the bacteria. And do this twice per day.

    Instead you inhale a mist for 10 minutes, and sit back and watch TV for the rest of the day. OOPS! I inhaled my dose one hour late. FM! But it still does not matter because the dose was inhaled, is accumulating directly in the lungs where the infection is challenging the patient . . . and guess what . . . killing the bacteria. The bottom line for ARDM is the logs of killed bacteria (Pseudomonas aeruginosa or Mycobacterium species other than TB and the number of patient that have "ZERO" bacteria in a sputum sample after 28 or 56 days.

    EOS.

    Based upon my treating animals for the same conditions we are describing for humans . . . I think liposoma Cipro once per day is a more easily administered and therapeutically beneficial outcome. But let's wait and see what the clinical trials data reveal. I would be surprised if ARDM does not surpass the results achieved for TOBI, Arikayce, Zith and others. Just my impression from treating 43 years of animals with respiratory infections.

    GLTAL

    Sentiment: Strong Buy

  • Reply to

    OT ... Check out PRTK

    by la.taupe Jun 17, 2016 7:27 AM
    rehdvm2004 rehdvm2004 Jun 21, 2016 5:07 PM Flag

    ARDM is liposomal Cipro for respiratory infections . . . while PRTK makes a novel tetracycline for skin infections and rosacea. Those dots do not connect or run in parallel. That is how you should contrast the two different categories of antibiotics. I know because I took Cipro for various infections (respiratory, cellulitis of the skin in my leg from a Brown Recluse Spider bite, and sinusitis). Cipro works well. Also took short treatments for rosacea and ureaplasma with doxycycline, so I know that antibiotic. So what you are proposing is "diversification" of investment in novel antibiotic?!? That is what it is on the face of the facts.

    GLTAL

    Sentiment: Strong Buy

  • rehdvm2004 by rehdvm2004 Jun 21, 2016 11:36 AM Flag

    I post this same info from time to time. Almost all (I do not know of any, but . . .) vaccine batch release test require dosing mice with the vaccine, waiting the required period for eliciting neutralizing antibodies and the challenging one group of mice with saline (or the vaccine vehicle where all animals are expected to live), one group with a low dose challenge of live infectious agent (again all are expected to live), one group with an intermediate dose of live infectious agent (all or most are expected to live) and one group with a high dose of live infectious agent (these mice got the short straw and most succumb). Then based upon an calculation, the manufacture puts the vaccine into vials (final product) and then they test the vaccine all over in mice again to make sure that a statistically significant number of vaccine vials have the same level of protection.

    So stupid comments like "the vaccine saves mice" . . . are just that ignorant . . . uninformed basher attempts to demonstrate they are who they are.

    GLTAL

    Sentiment: Strong Buy

  • Inovio is on the cusp of several break through vaccines that will be the "way forward" for pediatric and adult vaccinations for the next century:

    1. DNA Zika;
    2. DNA Ebola;
    3. DNA Hep C and not to be forgotten;
    4. DNA HPV for an alternative to cervical surgery and head and neck therapy.

    Take your pick each is a $Billion market.

    Look to marketing in 2017.

    GLTAL

    Sentiment: Strong Buy

  • rehdvm2004 rehdvm2004 Jun 19, 2016 2:47 PM Flag

    PS - That is not even counting the cancer vaccine projects.

    Sentiment: Strong Buy

  • rehdvm2004 rehdvm2004 Jun 19, 2016 2:46 PM Flag

    Inovio has many clinical trial prospects that are going to take a lot more $$$ in the next two years. Zika and Ebola on the infectious disease side, but these are currently infrequently transmitted and non-existent in the US. However, Inovio has also started vaccine studies on the No. 1 most transmitted and fatal disease in the US according to CDC. I get the alerts sent to my main e-mail and was shocked to find out what they announced on the Infectious Disease Advisor on June 10. Hepatitis C. So yes, Inovio needs more cash to keep all their trials moving along, but the benefit to risk ratio is worth every penny of buying more shares. Dilution is only self serving if there is no progress being made for at least one project. Inovio has quite a few that are progressing.

    GLTAL

    Sentiment: Strong Buy

  • Reply to

    Newest Annual Report and Proxy Statement

    by walktheline43 May 25, 2016 7:32 AM
    rehdvm2004 rehdvm2004 Jun 1, 2016 9:49 AM Flag

    They went with EMEA because Grifols is located in Spain, they have an "knowledgeable inside regulatory track" in Europe and the filing through ICH (Harmony) would be expedited anyway. I think that some of the hospitals that are participating are in the US and Canada, so the cross-filing is just a technicality. If they get two or more logs of kill against either Pseudomonas aeruginosa or Mycobacterium species . . . Pulmoquin and/or Lipoquin are going to be approved.

    GLTAL

    Sentiment: Strong Buy

INSM
13.27+0.07(+0.53%)Aug 30 4:00 PMEDT